Revenue segments as reported by the company.

Premiums

Product revenue

Administrative fees and other revenue

Net investment income

Net gains on financial instruments

Gain on sale of business

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit expense

Selling, general and administrative

Interest expense

Amortization of other intangible assets

Loss on extinguishment of debt

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Elevance Health Inc

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journey, connecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elevance Health reports robust Q4 earnings, eyes margin optimization

Elevance Health's strong Q4 2022 performance, strategic acquisitions, and focus on margin optimization position the company for continued growth. With a clear outlook for 2023, emphasizing membership expansion and margin recovery, the company is poised for success. Challenges in optimizing margins and managing cost structures are balanced by growth opportunities and strategic initiatives.

Elevance Health reports robust Q1 growth and innovation in healthcare

Elevance Health Inc demonstrated strong financial performance and growth in Q1 2023, driven by increased membership and solid operating results.
The company's focus on advocacy, innovation, and sustainability, along with strategic investments in healthcare capabilities, positions it for continued success.
While facing challenges in cost management and strategic partnerships, Elevance Health is well-positioned to capitalize on opportunities in specialty care and value-based models.
Overall, Elevance Health's commitment to whole health, innovation, and value-based care sets a positive trajectory for future growth and industry leadership.

Elevance Health Inc posts robust Q2 earnings, eyes value-based care

Elevance Health Inc reported strong Q2 earnings, raised adjusted EPS outlook to over $32.85 for the year, and emphasized a focus on value-based care and digital solutions. While facing margin pressure in Carelon, the company remains confident in its strategy execution and performance for 2023 and beyond.

Elevance Health excels in Q3, eyes growth through strategic actions

Elevance Health's Q3 performance was strong, with a focus on operational efficiency and strategic investments. Challenges in Medicare ratings were addressed through proactive measures, while opportunities lie in growth acceleration and strategic partnerships. The company remains on track to achieve its long-term growth targets.

Elevance Health Inc surpasses earnings expectations, eyes growth opportunities

Elevance Health Inc's strong financial performance in Q4 2023 and full-year results, coupled with strategic initiatives in expanding capabilities and enhancing operational efficiency, position the company for continued success. Challenges in commercial repricing and Medicaid dynamics are being addressed, while opportunities in Medicare Advantage and strategic investments offer avenues for growth.

Elevance Health posts robust Q1 earnings, eyes strategic growth

Elevance Health demonstrated strong financial performance in Q1, with revenue growth and margin expansion in key segments.
While facing challenges like potential Medicare rate cuts, the company is leveraging partnerships and acquisitions for growth.
Opportunities lie in expanding service offerings, geographic footprint, and optimizing Medicaid margins for long-term sustainability.

Elevance Health Inc reports robust earnings growth and strategic wins

Elevance Health's Q2 performance reflects strong earnings growth and reaffirmed guidance, driven by solid segment performance and new business wins.
The company's strengths lie in its high Medicare rating, robust revenue growth in services, and strategic focus on value creation.
Challenges include sustaining growth momentum, managing funding cuts, and effectively integrating recent acquisitions for long-term success.
Opportunities exist in accelerating capabilities, expanding market share, optimizing operations, and leveraging workplace recognition for talent attraction and innovation.

Elevance Health faces Medicaid challenges, sees growth in AI investments

Elevance Health's Q3 earnings were impacted by elevated medical costs in Medicaid, leading to a reduction in full-year outlook. Despite challenges in the Medicaid business, the company's Medicare Advantage and Commercial businesses are performing well. Investments in AI and expansion of Carelon Services present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.

UnitedHealth Group

The competitive benefits of being a BCBSA licensee has helped ELV grow its member base faster than UnitedHealth, especially on the higher margin commercial side. I pinpoint Elevance's strategy and what differentiates it from UnitedHealth. I cover several risk factors that could hurt Elevance's benefit costs - a key long-term driver of operating margins.

A Look At Elevance's Margin Dynamics

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?

Why Is Elevance Health (ELV) Up 0.1% Since Last Earnings Report?

Elevance Health (ELV) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Growth Investors Shouldn't Overlook Elevance Health (ELV)

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has assigned indicative Long-Term Issue Credit Ratings of “bbb” (Good) to subordinated issues, “bbb-” (Good) to preferred stock issues and “bbb+” (Good) to senior unsecured issues on the recently filed shelf registrations of Elevance Health, Inc. (Elevance Health) (Indianapolis, IN) [NYSE: ELV]. The outlook assigned to these Credit Ratings (ratings) is stable. Concurrently, AM Best has withdrawn the ratings of the previous shelf registration, which expire.

AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.'s New Shelf Registrations

INDIANAPOLIS--(BUSINESS WIRE)-- #AADMD--Elevance Health provides $1.42 million in grants for medical schools to implement IDD curriculum. Proposals for funding are currently being accepted.

Elevance Health and AADMD Launch Bold Initiative to Broadly Expand Physician Training on the Care of People with Intellectual and Developmental Disabilities

HealthEquity

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

ELV vs. HQY: Which Stock Is the Better Value Option?

The mean of analysts' price targets for Elevance Health (ELV) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 25.45% Upside in Elevance Health (ELV): Here's What You Should Know

With ELV's underlying markets growing at around 6-7% and the normalized FCF yield sitting at 6.8% at the moment, ELV should be able to deliver low double-digit returns. The medical membership structure and the venture into other business segments like PBM and healthcare services are similar to the market leader UnitedHealth Group. My DCF valuation indicates that ELV is undervalued, even when using growth rates that are lower than what I actually expect.

Elevance Health: An Overlooked Healthcare Gem?

Elevance Health (ELV) could produce exceptional returns because of its solid growth attributes.

Is Elevance Health (ELV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Elevance Health has left the S&P 500 in the dust over the past decade. The managed care company's growth story remains promising.

Elevance Health: Buy This Compounder For Growing Dividends

Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.

Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength

Elevance Health: A High Conviction Defensive Blue Chip Buy

Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.

Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View

Elevance Health, Inc. (NYSE:ELV ) Q3 2023 Earnings Conference Call October 18, 2023 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO John Gallina - CFO Peter Haytaian - President of Carelon Morgan Kendrick - President of Commercial and Specialty Health Benefits Division Felicia Norwood - President of Government Health Benefits Division Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Stephen Baxter - Wells Fargo Ben Hendrix - RBC Capital Markets Kevin Fischbeck - Bank of America Sarah James - Cantor Fitzgerald Michael Ha - Morgan Stanley Josh Raskin - Nephron Research Justin Lake - Wolfe Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Third Quarter Earnings Conference Call.

Elevance Health, Inc. (ELV) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Elevance Health (ELV) Q3 Earnings

Elevance Health (ELV) came out with quarterly earnings of $8.99 per share, beating the Zacks Consensus Estimate of $8.45 per share. This compares to earnings of $7.53 per share a year ago.

Elevance Health (ELV) Q3 Earnings Top Estimates

Elevance Health reported a better-than-expected third-quarter profit on Wednesday, helped by lower-than-expected medical costs for the health insurance provider.

Elevance Health beats third-quarter profit estimates

INDIANAPOLIS--(BUSINESS WIRE)---- $ELV #earnings--Elevance Health, Inc. (NYSE: ELV) reported third quarter 2023 results reflecting strong financial performance across the enterprise. “Elevance Health delivered another quarter of solid performance reflecting the strength and balance of our diversified portfolio of businesses, our continued investments in innovation and growth, and our relentless focus on affordability, simplicity, and customer experience,” said Gail K. Boudreaux, President and CEO. “With affordabi.

Elevance Health Reports Third Quarter 2023 Results

Archer-Daniels-Midland Company

Aflac

BHP Billiton

Cummins

Corteva Inc

Dominion Energy

Discover

Dow Inc

Con Ed

Emerson Electric

Fortune Brands Innovations Inc

FirstEnergy

W.W. Grainger

Intel

Johnson & Johnson

Nordstrom

Jackson Financial

KeyCorp

Kraft Heinz

Kroger

Lockheed Martin

LyondellBasell Industries

Dividend Income Summary: Lanny's September 2023 Summary

Elevance Health (ELV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Elevance Health (ELV) This Earnings Season?

In the most recent trading session, Elevance Health (ELV) closed at $454.11, indicating a +0.13% shift from the previous trading day.

Elevance Health (ELV) Rises As Market Takes a Dip: Key Facts

The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.

Can Elevance's (ELV) Q3 Earnings Beat on Carelon Strength?

Elevance Health (ELV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Elevance Health (ELV) Upgraded to Buy: What Does It Mean for the Stock?

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or HealthEquity (HQY). But which of these two companies is the best option for those looking for undervalued stocks?

ELV vs. HQY: Which Stock Should Value Investors Buy Now?

Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Elevance Health Inc Stock (ELV)